Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
NCT00294190 · View on ClinicalTrials.gov ↗
Study Summary
This proposed phase II trial will investigate weekly topotecan at a higher dose than was used in the previous trials in an attempt to achieve improved response rates and disease control without added toxicity. To help ameliorate the fatigue, planned rest weeks will be incorporated into the schedule. This trial will be the first clinical trial to evaluate a higher dose of weekly topotecan in the treatment of extensive-stage SCLC.
Conditions Studied
Interventions
- DRUG Topotecan
Study Locations (13)
Florida
- Florida Cancer Specialists — Fort Myers
- Watson Clinic Center for Cancer Care and Research — Lakeland
- Florida Hospital Cancer Institute — Orlando
Tennessee
- Chattanooga Oncology Hematology Associates — Chattanooga
- Tennessee Oncology, PLLC — Nashville
Arkansas
- Northeast Arkansas Clinic — Jonesboro
Georgia
- Northeast Georgia Medical Center — Gainesville
Kentucky
- Consultants in Blood Disorders and Cancer — Louisville
Louisiana
- Hematology Oncology Life Center — Alexandria
Michigan
- Grand Rapids Clinical Oncology Program — Grand Rapids
Nebraska
- Methodist Cancer Center — Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294190
The ClinicalTrials.gov registry entry for NCT00294190 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 63 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention — of which Topotecan is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00294190 reports 13 study locations spanning 10 distinct geographic areas — top geographies include Florida, Tennessee, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00294190 about?
NCT00294190 is a clinical study titled "Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer". This proposed phase II trial will investigate weekly topotecan at a higher dose than was used in the previous trials in an attempt to achieve improved response rates and disease control without added toxicity. To help ameliorate the fatigue, planned rest weeks will be incorporated into the schedule....
What is the current status of trial NCT00294190?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2006-02. Estimated completion is 2009-07.
What conditions does trial NCT00294190 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer, Carcinoma, Small Cell. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00294190?
The interventions under investigation include: Topotecan (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00294190?
This trial is sponsored by SCRI Development Innovations, which has 63 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00294190 being conducted?
This trial has 13 study locations across Arkansas, Florida, Georgia, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.